今日,医药人的朋友圈被一条重磅消息刷屏:默沙东与Ridgeback Biotherapeutics公司宣布,其一款在研口服抗病毒小分子药物可显著减少因新冠而住院或死亡的风险。基于积极临床结果,独立的数据监察委员会也推荐提前结束临床试验。这款创新疗法有望成为全球抗新冠武器库中的重要一员,为早日终结疫情贡献自己的一份力量。

▲Molnupiravir在临床试验中取得了积极成果(图片来源:Credit - 默沙东)

▲部分位于临床研发阶段的口服抗新冠病毒药物(数据来源:参考资料[2],Evaluate Pharma & clinicaltrials.gov;制图:药明康德内容团队)

来源:药明康德

参考资料:
[1] Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study, Retrieved October 1, 2021, from https://www.businesswire.com/news/home/20211001005189/en/Merck-and-Ridgeback%E2%80%99s-Investigational-Oral-Antiviral-Molnupiravir-Reduced-the-Risk-of-Hospitalization-or-Death-by-Approximately-50-Percent-Compared-to-Placebo-for-Patients-with-Mild-or-Moderate-COVID-19-in-Positive-Interim-Analysis-of-Phase-3-Study
[2] Unexpected win opens the way to an oral Covid antiviral, Retrieved October 1, 2021, from https://www.evaluate.com/vantage/articles/news/trial-results/unexpected-win-opens-way-oral-covid-antiviral
版权声明:部分文章在推送时未能与原作者取得联系。若涉及版权问题,敬请原作者联系我们。联系方式:[email protected]
继续阅读
阅读原文